Less is more for Siemens' medtech:
This article was originally published in Clinica
Executive Summary
Siemens' medtech division had sales of DM5 billion ($2.8 billion) in the nine months ended June 30 1998, down from DM5.1 billion in the previous period. The German company says this represents a 12% increase when adjusted for acquisitions, divestments and organisational changes. Adjusted figures for new orders in the division rose 16% to DM5.8 billion. International sales are mainly responsible for the increase in turnover. Total sales were DM81.9 billion, up 15%.
You may also be interested in...
Prestige Expands UK Eye Care Range In Response To Consumer Demand
A “great consumer response” to TheraTears in the UK leads Prestige Consumer Healthcare to add TheraTears 5-in-1 Irritation and Redness eye drops to the range.
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.